Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹2256 Cr.
Stock P/E
29.1
P/B
—
Current Price
₹504.7
Book Value
₹ 0
Face Value
2
52W High
₹737
52W Low
₹ 377.3
Dividend Yield
0.4%

Vimta Labs Overview

Business

Vimta Labs Ltd. is a contract research and testing organization (CRTO) based in India. The company provides a comprehensive range of analytical testing, pre-clinical and clinical research, and consulting services. Its core business model involves offering specialized scientific services to clients across diverse sectors including pharmaceuticals, food & agriculture, water, environment, and consumer products. Vimta Labs makes money by charging fees for these services, which are critical for quality control, safety assessment, regulatory compliance, and product development for its clients.

Revenue Mix

Vimta Labs primarily operates in two broad segments:

Analytical Testing Services: This segment provides testing for food and agriculture products, water, environmental samples, pharmaceutical raw materials and finished products, consumer products, and more. It focuses on chemical, microbiological, and physical analysis for quality, safety, and regulatory compliance.

Contract Research Services (CRO): This segment includes pre-clinical toxicology studies, clinical research (Bioavailability/Bioequivalence - BA/BE studies), and other specialized research services for pharmaceutical and biopharmaceutical companies.

While exact revenue contributions can fluctuate, both segments are significant contributors, with analytical testing generally forming a larger and more diversified base, complemented by the specialized, high-value contract research.

Industry

Vimta Labs operates in the growing and increasingly regulated Indian CRTO market. The industry is characterized by a mix of specialized domestic players and international CROs. Vimta Labs is one of the established and prominent players in India, particularly recognized for its diversified analytical testing capabilities across multiple sectors and its expertise in GLP-compliant pre-clinical and BA/BE studies. It holds numerous national and international accreditations (NABL, GLP, cGMP, USFDA, OECD) which are crucial for its positioning as a reliable partner for regulatory submissions.

MOAT

Vimta Labs possesses several durable advantages:

Accreditations & Certifications: Extensive list of national (NABL) and international (USFDA, OECD GLP, etc.) accreditations acts as a significant barrier to entry and builds trust with clients, especially for services requiring global regulatory acceptance.

Track Record & Reputation: Decades of experience and a strong reputation for scientific integrity and quality are critical in a services business where trust and reliability are paramount.

Diversified Service Portfolio: Broad range of services across multiple industries (pharma, food, environment) reduces dependence on any single sector and provides cross-selling opportunities.

Specialized Expertise: A team of experienced scientists and state-of-the-art infrastructure enables the company to handle complex analytical and research projects.

Growth Drivers

Increased Regulatory Scrutiny: Growing regulatory emphasis on quality, safety, and environmental compliance across industries (food, pharma, consumer goods) drives demand for independent testing.

Outsourcing Trends: Pharmaceutical, food, and other manufacturing companies continue to outsource R&D and testing functions to specialized CRTOs to reduce costs, access expertise, and streamline operations.

Growing Pharma & Healthcare Market: Expansion in the Indian pharmaceutical industry and increased R&D spending directly boosts demand for CRO services.

Food Safety & Consumer Awareness: Rising consumer awareness about food quality and safety, coupled with evolving food safety standards, fuels demand for food testing.

Environmental Concerns: Increasing focus on environmental monitoring and sustainability drives demand for water and environmental testing services.

Risks

Regulatory Changes: Any adverse changes in domestic or international regulations, accreditation standards, or testing methodologies could impact operations or require significant investment.

Intense Competition: The CRTO market is competitive, with both domestic and international players vying for market share, potentially leading to pricing pressures.

Economic Slowdown: A downturn in the global or domestic economy could lead clients to cut R&D and testing budgets, impacting revenue.

Talent Acquisition & Retention: Reliance on skilled scientific and technical personnel means challenges in attracting and retaining talent can impact service delivery and growth.

Technological Obsolescence: The need for continuous investment in advanced instrumentation and technology to remain competitive and meet evolving client needs.

Management & Ownership

Vimta Labs was founded by Dr. S. P. Vasireddi, who continues to serve as the Chairman and Managing Director. The company has a stable and experienced management team, with strong promoter involvement. Promoter ownership typically remains significant, indicating a strong long-term commitment to the business. The management is generally perceived as scientifically driven and focused on quality and regulatory compliance.

Outlook

Vimta Labs is well-positioned in a structurally growing industry driven by increasing regulatory demands and outsourcing trends. Its diverse service portfolio, strong accreditations, and established reputation provide a solid foundation. The company benefits from secular tailwinds in pharmaceuticals, food safety, and environmental testing. However, it operates in a competitive landscape requiring continuous investment in technology and talent. Its ability to scale operations efficiently, adapt to evolving scientific and regulatory landscapes, and effectively manage competition will be key to sustaining its growth trajectory.

Vimta Labs Share Price

Live · BSE / NSE · Inception: 1990
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Vimta Labs Quarterly Results

#(Fig in Cr.) Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 80 77 82 83 66 75 80 82 85 90
Other Income 1 1 1 1 2 1 0 1 1 1
Total Income 81 79 82 84 68 75 80 82 85 91
Total Expenditure 54 56 58 59 48 51 55 57 55 57
Operating Profit 26 23 25 25 19 25 25 25 31 34
Interest 1 1 0 0 1 1 1 0 0 1
Depreciation 8 8 8 8 9 8 8 8 8 10
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 18 14 17 16 10 16 16 17 22 24
Provision for Tax 5 4 4 4 2 3 4 4 5 6
Profit After Tax 13 10 13 12 8 12 12 12 17 18
Adjustments 0 0 0 0 -2 -2 0 0 -2 4
Profit After Adjustments 13 10 13 12 6 10 12 12 15 21
Adjusted Earnings Per Share 3 2.3 2.9 2.8 1.4 2.3 2.8 2.8 3.4 4.8

Vimta Labs Profit & Loss

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
Net Sales 181 211 278 318 318 337
Other Income 3 1 1 3 4 3
Total Income 184 212 280 322 322 338
Total Expenditure 151 158 198 223 231 224
Operating Profit 33 54 82 98 91 115
Interest 4 2 1 3 2 2
Depreciation 21 23 23 31 34 34
Exceptional Income / Expenses 0 0 -1 0 0 0
Profit Before Tax 8 29 56 65 54 79
Provision for Tax 1 7 14 17 13 19
Profit After Tax 7 21 41 48 41 59
Adjustments 0 0 0 0 0 2
Profit After Adjustments 7 21 41 48 41 60
Adjusted Earnings Per Share 1.5 4.8 9.3 10.9 9.2 13.8

Vimta Labs Balance Sheet

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Shareholder's Funds 173 194 234 282 320
Minority's Interest 0 0 0 0 0
Borrowings 5 14 13 10 9
Other Non-Current Liabilities 9 11 11 9 9
Total Current Liabilities 58 54 48 57 54
Total Liabilities 245 273 305 358 392
Fixed Assets 138 135 169 175 171
Other Non-Current Assets 11 28 12 20 64
Total Current Assets 96 111 124 164 158
Total Assets 245 273 305 358 392

Vimta Labs Cash Flow

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Opening Cash & Cash Equivalents 3 6 6 11 31
Cash Flow from Operating Activities 24 37 59 88 61
Cash Flow from Investing Activities -21 -32 -38 -57 -76
Cash Flow from Financing Activities -1 -5 -17 -11 -2
Net Cash Inflow / Outflow 3 1 5 20 -17
Closing Cash & Cash Equivalent 6 6 11 31 13

Vimta Labs Ratios

# Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Earnings Per Share (Rs) 1.55 4.84 9.35 10.88 9.25
CEPS(Rs) 6.28 10.06 14.62 17.82 16.96
DPS(Rs) 0 1 1 1 1
Book NAV/Share(Rs) 39.09 43.96 52.26 62.23 70.59
Core EBITDA Margin(%) 16.57 25.14 28.85 29.83 27.27
EBIT Margin(%) 6.66 14.58 20.55 21.26 17.79
Pre Tax Margin(%) 4.58 13.55 20.01 20.43 17.12
PAT Margin (%) 3.79 10.16 14.85 15.14 12.89
Cash Profit Margin (%) 15.37 21.11 23.24 24.79 23.63
ROA(%) 2.79 8.25 14.29 14.53 10.93
ROE(%) 3.96 11.66 19.43 19.02 13.94
ROCE(%) 5.84 14.25 23.92 24.59 17.81
Receivable days 116.83 113.74 98.63 90 95.75
Inventory Days 34.6 27.52 20.99 22.94 27.13
Payable days 0 1549.17 0 0 0
PER(x) 19.14 16.63 16.86 14.44 24.04
Price/Book(x) 0.76 1.83 3.01 2.52 3.15
Dividend Yield(%) 0 1.24 0.63 0.64 0.45
EV/Net Sales(x) 0.87 1.8 2.53 2.11 3.08
EV/Core EBITDA(x) 4.78 7.06 8.62 6.82 10.78
Net Sales Growth(%) 0 16.58 32.09 14.34 0.02
EBIT Growth(%) 0 155.16 86.22 18.29 -16.32
PAT Growth(%) 0 212.71 93.09 16.55 -14.87
EPS Growth(%) 0 212.71 93.09 16.45 -15.02
Debt/Equity(x) 0.19 0.16 0.08 0.05 0.06
Current Ratio(x) 1.67 2.05 2.6 2.86 2.91
Quick Ratio(x) 1.37 1.78 2.24 2.46 2.46
Interest Cover(x) 3.2 14.16 38.17 25.57 26.67
Total Debt/Mcap(x) 0.25 0.09 0.03 0.02 0.02

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 0% +15% — —
Operating Profit CAGR -7% +19% — —
PAT CAGR -15% +25% — —
Share Price CAGR -26% +20% +28% +26%
ROE Average +14% +17% +14% +14%
ROCE Average +18% +22% +17% +17%

Vimta Labs Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 35.67 %
FII 4.42 %
DII (MF + Insurance) 0.37 %
Public (retail) 59.55 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 36.9236.8936.8936.7636.736.6735.9935.935.8535.67
FII 5.135.163.313.813.663.494.334.594.894.42
DII 1.51.4901.161.431.420.870.110.140.37
Public 56.4556.4659.858.2758.258.4258.859.4159.1259.55
Others 0000000000
Total 100100100100100100100100100100

Vimta Labs Peer Comparison

Business Support Edit Columns

Vimta Labs Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Vimta Labs Pros & Cons

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 35.67%.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp